Shire faces RoI test under vision-loving new CEO
This article was originally published in Scrip
Executive Summary
Shire Pharmaceuticals is known for its acquisitive buy-late, maximize-market strategy. Flemming Ornskov, the company's new CEO, plans to continue that approach, firstly by applying it to acquisitions in ophthalmology, an area in which he has specialized. However, with many recent acquisitions yet to mature to revenue-generation, and with big indication areas for Shire like ADHD at risk from generic and branded competition, the pressure is on the new CEO – even before he officially starts work.
You may also be interested in...
Scrip Asks…What Does 2022 Hold For Biopharma? Part 7: People And Planet
Addressing health care inequities, providing a nurturing environment for employees and learning from the pandemic were among the aims expressed by executives surveyed by Scrip.
Scrip Asks…What Does 2022 Hold For Biopharma? Part 6: Digital And Telehealth
Digital and telehealth solutions took off during COVID-19 and industry observers expect them to advance still further in the coming year. Coupling enhanced patient experience with rich opportunities to use associated data to enhance product development and health care practice, benefits should accrue to industry, health care practitioners, health systems and patients alike.
Scrip Asks…What Does 2022 Hold For Biopharma? Part 5: Clinical Trials
The COVID-19 pandemic drove huge shifts in clinical trial practice and the transformation is expected to continue even after the global health emergency abates. Industry leaders sharing their predictions around clinical development homed in on decentralized trials, digitization and data tools as key topics for 2022.